2-(4-methylphenyl)-1-(4-methylsulfanylphenyl)ethanone | 708276-16-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-(4-methylphenyl)-1-(4-methylsulfanylphenyl)ethanone
• 英文别名: 1-(4-(methylthio)phenyl)-2-p-tolylethanone
• CAS: 708276-16-8
• 化学式: C₁₆H₁₆OS
• mdl: MFCD22255896
• 分子量: 256.368
• InChiKey: NWVZUXAPFWIGQD-UHFFFAOYSA-N

物化性质

• 熔点：
  39 °C
• 沸点：
  415.1±33.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.187
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-methylphenyl)-1-(4-methylsulfanylphenyl)ethanone 在 sodium methylate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  5-芳基-6-（4-甲基磺酰基）-3-（甲硫基）-3-1,2,4-三嗪作为选择性环加氧酶-2抑制剂的合成，对接模拟，生物学评估和3D-QSAR研究

  摘要：

  合成了一系列的5-芳基-6-（4-甲基磺酰基）-3-（甲硫基）-1，2，4-三嗪衍生物，它们具有抑制COX-1 / COX-2的活性以及体内抗炎作用。并评估了镇痛效果。所有化合物均显示出对COX-2的强抑制作用，IC 50值在0.1–0.2μM的范围内，并且在大多数情况下，在剂量为3和6 mg / kg时，其消炎和镇痛作用均比消炎痛强。其中，5-（4-氯苯基）-6-（4-（甲基磺酰基）苯基）-3-（甲硫基）-1,2,4-三嗪（9c）是最有效和选择性最强的COX-2化合物。其选择性指数395与塞来昔布相当（SI = 405）。评估9c的抗炎和镇痛作用与吲哚美辛相比，它具有更高的药效，因此可以被认为是进一步开发药物的有前途的候选药物。此外，这些化合物的亲和力数据通过酶对接模拟和k-最近邻分子场分析法进行的3D-QSAR研究得到了合理化。

  DOI：

  10.1016/j.bmc.2013.12.002
• 作为产物：
  描述：

  茴香硫醚 、 对甲苯乙酰氯 在 三氯化铝 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 以66%的产率得到2-(4-methylphenyl)-1-(4-methylsulfanylphenyl)ethanone
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 2-Phenylpyran-4-ones:  A New Class of Orally Active Cyclooxygenase-2 Inhibitors

  摘要：

  A series of 2-phenylpyran-4-ones were prepared and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective COX-2 inhibitors were identified. Compounds having a p-methylsulfone group at the 2-phenyl ring showed the best COX-2 inhibitory activity. The introduction of a substituted phenoxy ring at position 3 enhanced both the in vitro and in vivo activity within the series. A selected group of 3-phenoxypyran-4-ones exhibited excellent activity in an experimental model of pyresis. The in vivo antiinflammatory activity of these compounds was confirmed with the evaluation of their antiarthritic and analgesic effectiveness. Moreover, their pharmacokinetic profile in rats is compatible with a once a day administration by oral route in humans. Within this novel series, compounds 21, 31, 34, and 35 have been selected for further preclinical. and clinical evaluation.

  DOI：

  10.1021/jm049882t

文献信息

• Design, Synthesis and<i>In Vitro</i>Study of 5,6-Diaryl-1,2,4-triazine-3-ylthioacetate Derivatives as COX-2 and β-Amyloid Aggregation Inhibitors
  作者：Sakineh Dadashpour、Tuba Tuylu Kucukkilinc、Oya Unsal Tan、Keriman Ozadali、Hamid Irannejad、Saeed Emami

  DOI：10.1002/ardp.201400400

  日期：2015.3

  6‐diaryl‐1,2,4‐triazine‐3‐ylthioacetate derivatives were synthesized and their chemical structures were confirmed by NMR, IR and MS spectra. Further in vitro COX‐1/COX‐2 evaluations revealed that compound 6c (COX‐2 IC50 = 10.1 μM, COX‐1 IC50 = 88.8 μM) is the most selective COX‐2 inhibitor while maintaining residual inhibition of COX‐1. In order to evaluate their potential use against AD, an in vitro evaluation

  为了寻找新的环氧合酶 (COX)-2 抑制剂来治疗阿尔茨海默病 (AD) 等炎症性疾病，将羧酸乙酯侧链添加到 5-(4-氯苯基)-6-(4-(甲基磺酰基)苯基)-3-(甲硫基)-1,2,4-三嗪（先导化合物 II）通过与 Arg120 相互作用维持对 COX-1 的残留抑制。对 COX-1/COX-2 活性位点的初步分子对接研究确实证实了我们的假设。因此，合成了一系列 5,6-二芳基-1,2,4-三嗪-3-基硫代乙酸乙酯衍生物，并通过 NMR、IR 和 MS 光谱证实了它们的化学结构。进一步的体外 COX-1/COX-2 评估显示化合物 6c（COX-2 IC50 = 10.1 μM，COX-1 IC50 = 88.8 μM）是最具选择性的 COX-2 抑制剂，同时保持对 COX-1 的残留抑制。为了评估它们对 AD 的潜在用途，进行了 β-淀粉样蛋白原纤维形成的体外评估。结果表明，原型化合物
• Synthesis and SAR of a New Series of COX-2-Selective Inhibitors:  Pyrazolo[1,5-<i>a</i>]pyrimidines
  作者：Carmen Almansa、Alberto F. de Arriba、Fernando L. Cavalcanti、Luis A. Gómez、Agustí Miralles、Manuel Merlos、Julián García-Rafanell、Javier Forn

  DOI：10.1021/jm0009383

  日期：2001.2.1

  The synthesis and pharmacological activity of a series of bicyclic pyrazolo[1,5-a]pyrimidines as potent and selective cyclooxygenase-2 (COX-2) inhibitors are described. The new compounds were evaluated both in vitro (COX-1 and COX-2 inhibition in human whole blood) and in vive (carrageenan-induced paw edema and air-pouch model). Modification of the pyrimidine substituents showed that 6,7-disubstitution provided the best activity and led to the identification of 3-(4-fluorophenyl)-6,7-dimethyl-2-(4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidine (10f) as one of the most potent and selective COX-2 inhibitor in this series.
• Synthesis and biological evaluation of 2,3-diarylpyrazines and quinoxalines as selective COX-2 inhibitors
  作者：Sunil K. Singh、V. Saibaba、V. Ravikumar、Santosh V. Rudrawar、Pankaj Daga、C.Seshagiri Rao、V. Akhila、P. Hegde、Y.Koteswar Rao

  DOI：10.1016/j.bmc.2004.01.033

  日期：2004.4

  Several 2,3-diaryl pyrazines and quinoxalines with 4-sulfamoyl (SO2NH2)/methylsulfonyl (SO2Me)-phenyl pharmaco-phores have been synthesized and evaluated for the cyclooxygenase (COX-1/COX-2) inhibitory activity. Smaller groups such as methoxy, methyl and fluoro when substituted at/around position-4 of the adjacent phenyl ring, have great impact on the selective COX-2 inhibitory activity of the series. Many potential compounds were obtained from a brief structure-activity relationship (SAR) study. Two of these, compounds 11 and 25 exhibited excellent in vivo activity in the established animal model of inflammation. Since compound 25 possessed an amenable sulfonamide group, two of its prodrugs 48 and 49 were also synthesized. Both of them have excellent in vivo potential, and represent a new class of COX-2 inhibitor. (C) 2004 Elsevier Ltd. All rights reserved.
• Synthesis and antiseizure activity of (E)-1,2-diarylethylidenehydrazine carboximidamides against tonic-clonic seizures: an intracerebroventricular and electrophysiological study
  作者：Fariba Abedi Firouzjaei、Elmira Heidarli、Shabnam Ravan、Sayed Masoud Hosseini、Nima Naderi、Kiarash Almasyan、Afshin Sarvary、Hamid Irannejad

  DOI：10.1007/s00044-020-02576-7

  日期：2020.8

  A series of (E)-1,2-diarylethylidenehydrazine carboximidamides2a-jwere synthesized and characterized by NOESY experiment as anticonvulsant agents and their antiseizure activity was evaluated by intracerebroventricular administration of compounds. Most of the compounds had significant protection against tonic-clonic seizures and2awas found to be as equipotent as carbamazepine in seizures control. In order to find their anticonvulsant mechanism of action,2awas subjected to further electrophysiological studies using patch-clamp technique. The results confirmed that this compound is neither a voltage-gated sodium channel blocker nor a NMDA/AMPA antagonist. Although2adid not show any direct GABA agonistic activity, it could decrease EPSP and increase IPSP frequency without any change in amplitude. Finally, the results indicated most likely a presynaptic GABA-mediated mechanism of2afor its antiseizure activity such as inhibition of the GABA-T which was validated by molecular docking.
• Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, OH scavenging and anti-adhesive activities
  作者：Michael Scholz、Holger K. Ulbrich、Oliver Soehnlein、Lennart Lindbom、Andreas Mattern、Gerd Dannhardt

  DOI：10.1016/j.bmc.2008.11.074

  日期：2009.1

  Three series of non-steroidal anti-inflammatory drugs (NSAIDs) inhibiting the cyclooxygenase/5-lipoxygenase (COX/5-LOX) pathways as such as formation of hydroxyl radicals and adhesion were prepared: 4,5-diaryl isothiazoles, 4,5-diaryl 3H-1,2-dithiole-3-thiones and 4,5-diaryl 3H-1,2-dithiole-3-ones. The aim of the present study was to develop substances which can intervene into the inflammatory processes via different mechanisms of action as multiple target non-steroidal anti-inflammatory drugs (MTNSAIDs) with increased anti-inflammatory potential. The current lead 11a was evaluated in COX-1/2, 5-LOX and (OH)-O-center dot scavenging in vitro assays and in a static adhesion assay where it proved to inhibit adhesion. Moreover, 11a treatment attenuated expression of macrophage adhesion molecule-1 (Mac-1) on extravasated polymorphonuclear leukocytes (PMNs) which indicates that the activation was reduced. The assays used are predictive for the in vivo efficacy of test compounds as shown for 11a in a peritonitis model of acute inflammation in mice. Thus, the novel 5-LOX/COX and (OH)-O-center dot inhibitor 11a possesses anti-inflammatory activity that, in addition to COX/5-LOX inhibition, implicates effects on leukocyte-endothelial interactions. (C) 2008 Elsevier Ltd. All rights reserved.